Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 14Gynecologic 7Gastrointestinal 5Other solid neoplasm 3CNS 3Breast 3Other hematologic neoplasm 2Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 3Inflammatory Breast Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × nintedanib × Breast × Clear all
NCT01658462 2026-03-16

VAROCE

Centre Oscar Lambret

Phase 2 Completed
51 enrolled
Breast

Breast Neoplasms

NCT02619162 2019-07-23

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Centro Nacional de Investigaciones Oncologicas CARLOS III

Phase 1 Completed
25 enrolled
Breast

Breast Neoplasms

NCT02389764 2019-07-17

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

M.D. Anderson Cancer Center

Phase 2 Terminated
10 enrolled 9 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡